Aoyagi T, Wada T, Tanaka T, Hara T, Umeda T, Niijima T, Umezawa H
Biochem Int. 1984 Apr;8(4):537-43.
Serum levels of various hydrolytic enzymes in prostatic cancer patients with or without bone metastasis were compared with those in patients with prostatic hypertrophy and in the control subjects. The enzymes tested included 11 aminopeptidases, 2 endopeptidases, dipeptidyl carboxypeptidase, esterase, acetyl cholinesterase, and RNase. Although most of the enzymatic levels tended to be decreased in the cancer patients without bone metastasis, they tended to be increased in those with metastasis as well as in the patients with prostatic hypertrophy. Thus, bone metastasis is an important factor affecting the serum levels of hydrolytic enzymes in cancer patients. Of the enzymes tested, RNase was unique in that its serum levels were significantly increased regardless of the existence of bone metastasis. This enzyme may become a marker of malignancy.
对伴有或不伴有骨转移的前列腺癌患者血清中各种水解酶水平，与前列腺增生患者及对照受试者的相应水平进行了比较。所检测的酶包括11种氨肽酶、2种内肽酶、二肽基羧肽酶、酯酶、乙酰胆碱酯酶和核糖核酸酶。尽管大多数酶水平在无骨转移的癌症患者中往往降低，但在有转移的患者以及前列腺增生患者中则往往升高。因此，骨转移是影响癌症患者血清水解酶水平的一个重要因素。在所检测的酶中，核糖核酸酶很独特，其血清水平无论有无骨转移均显著升高。这种酶可能成为恶性肿瘤的一个标志物。
